NewAmsterdam Pharma Co N.V.
Datakwaliteit: 100%
NAMSW
Nasdaq
Manufacturing
Chemicals
€ 23,40
▼
€ 0,10
(-0,43%)
Marktkapitalisatie: 2,78 B
Prijs
€ 23,50
Marktkapitalisatie
2,78 B
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -147,78 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-50,61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-27,06%
Boven sectorgemiddelde (-53,41%)
ROIC-23,67%
Net Margin-905,74%
Op. Margin-1002,90%
Veiligheid
Debt / Equity
N/A
Current Ratio12,57
Interest CoverageN/A
Waardering
PE (TTM)
-13,65
Onder sectorgemiddelde (-1,48)
P/B Ratio3,82
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -13,7 | -1,5 |
| P/B | 3,8 | 1,6 |
| ROE % | -27,1 | -53,4 |
| Net Margin % | -905,7 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -50,61% | Revenue Growth (3Y) | 26,38% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 22,50 M | Net Income (TTM) | -203,82 M |
| ROE | -27,06% | ROA | -25,45% |
| Gross Margin | N/A | Operating Margin | -1002,90% |
| Net Margin | -905,74% | Free Cash Flow (TTM) | -147,78 M |
| ROIC | -23,67% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 12,57 |
| Interest Coverage | N/A | Asset Turnover | 0,03 |
| Working Capital | 674,06 M | Tangible Book Value | 728,07 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -13,65 | Forward P/E | N/A |
| P/B Ratio | 3,82 | P/S Ratio | 123,67 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -5,31% | ||
| Market Cap | 2,78 B | Enterprise Value | 2,24 B |
| Per Share | |||
| EPS (Diluted TTM) | -1,72 | Revenue / Share | 0,19 |
| FCF / Share | -1,25 | OCF / Share | -1,25 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 72,51% |
| SBC-Adj. FCF | -201,18 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 22,50 M | 45,56 M | 14,09 M |
| Net Income | -203,82 M | -241,60 M | -176,94 M |
| EPS (Diluted) | -1,72 | -2,56 | -2,15 |
| Gross Profit | — | — | — |
| Operating Income | -225,68 M | -176,29 M | -182,97 M |
| EBITDA | — | — | — |
| R&D Expenses | 141,83 M | 151,41 M | 159,42 M |
| SG&A Expenses | 106,35 M | 70,45 M | 37,63 M |
| D&A | 220.000,0 | 113.000,0 | 49.000,0 |
| Interest Expense | — | 287.000,0 | 287.000,0 |
| Income Tax | -1.000,0 | -1.000,0 | 27.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 769,28 M | 864,62 M | 347,10 M |
| Total Liabilities | 85,85 M | 107,12 M | 58,70 M |
| Shareholders' Equity | 683,43 M | 757,50 M | 288,39 M |
| Total Debt | — | — | — |
| Cash & Equivalents | 490,00 M | 771,74 M | — |
| Current Assets | 675,70 M | 863,41 M | 346,79 M |
| Current Liabilities | 85,79 M | 106,92 M | 49,90 M |
{"event":"ticker_viewed","properties":{"ticker":"NAMSW","listing_kind":"stock","pathname":"/stocks/namsw","exchange":"Nasdaq","country":"US"}}